Zynext Ventures USA LLC, the venture capital arm of Zydus Lifesciences, has announced an investment in Illexcor Therapeutics, a biopharmaceutical company pioneering next-generation oral therapies for sickle cell disease (SCD). This strategic investment highlights Zynext Ventures’ focus on supporting healthcare innovations that address critical unmet medical needs. A Novel Approach to Treating Sickle Cell Disease …